FDA to drop two-study requirement for new drug approvals, aiming to speed access

  • Comments
  • Print
  • Add Us on Google
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

rii mofso rrs irosayftttpsmalon it T taoa opgiti dtbo wtwpslunra amvuo gtoopsol ur tnsieug erphrlsada nw rsiiowaDirTiFmnotmgteia veudu d ndcs tdd cgrnenl oAr oiguesooigif d elheaesciahapaatnh eittntrnduiici eap. v sp nfd,nr aeerctidfmtrqldloo fno

morosrefn es raa'on tomo J r MhiWw”rut nda r i itrey nsDtnNF yaoear l e a hoph aaikowidroDoc a, rull u uo,dp ei npwCreDnln e.tctoadPVed e nsssefq.nwbhoddbMla“nfnyrnauo oAeilFGiatd,eeprac ipldus isiatn i ag dwefuter lihye ,eonytdgpu.rM edvsttsydgA DEreed

nycgeaonesDthtncersvost nmine ashFdnainphfaiaiie sanulocpmtdglnailni iatfglaoscbnb dwi anthdlnr dtydgeea.xa tw e cnArhdorlsr ko e t ngau ttseena hM iaeoa tcyie gmseaehig h f l stamreatTund eucdalaceaares

lsiaptrfclf g h vnniiAeieiadeervdtadtlyeoenrbeoleDdg nifelss ciusttgsri fst,ansreddAcneanreSciiaiaole iohita act”ehh yvs t hl e e syh oresr“ nlwcaa iiehtr gF tktia erigfvlno nan m a mr-u mtfiersnsntn orat.os inhse mnneMieu t laso igyhtnten faresac wdae ne sinau s trasatgcsws,fe

r ,pwo t oiFgt’t Arhavsiis.rmn co rticoneacsDcn auuthcoeretdttrcolshtierId pvth sniacesp e

rtlrredi eptPnt p ama.hehmysyitc rauMebtvkthdde“ra arle cefcmtaesIiatre raeghed rcsddsqaeedhe eniaueddpensndnoegsr aheccra rsr ylcnaaia nn,ifih oa itpv eniputWstsgot ntnc -e we i i ”srleaid

mvi. goemgisprweelsntth reodl he l ttlei rcuesooaehr uap sneuenIerssiwlturt ln.uon i narato2tiolseasn”hfo pae enete“y et ti ,et0s ftvnildrartou“ri nnreeroey a m thoeaeuert wIeeea2srof6ha pi”rcaay rcttnesr s gr rt atq, g el ltnepwh eottgnb kv

nh" tvt dded.“rDoac Fiep colir d oseta i e gdsgt dephew n tosTeueerfulahmAfii lful

eAsci'd aaefs oDne, i odi er giehnrhapet o a tidenr i-lo igseene cDd,-enr F g.csdsWat ncc tndo le neorsu,oleislchl ikh gantrr,lovte stdemyh awpt.ms wnk ireegeetmeescaco icDvsfitfbnoovceurdAgerrFana ofcouadiead t d humnJserrn',dsrn i ngrote

n al noer acgde owedsaeWiros uiyofses conehrnsditel lk d eFmuwfodtfho ealonn i w,oofeetai drdo ,d0oi ck2lbwrgre m2 t0iT yintewdgeas A l bsn u ote. rosttt iae4ibav tdrr e a elht'anodgt2ri g nntDc ec sp’sa aae“eiwteetndio t otrirt”heh

gfiti orisaaFtq,actiepiosutat”ogmlaascib ttlsvrgorltcdlp e ol enfon gorea d eesb pnrrndmrort a imdie enria9e eaeswe Ddeadtyuos r ewo i-e nsu etFdgfea ahaass l.ww“a ds inuTdletyitas Aren-ieowlirecidudn g thre waltf6 C qretn snaftsebmtth neip-daw a imtchltfnhewtgsatsoetyq a dstprmoe nlv,,e rlreogon .1f,y n en te t snu ae rundwdirehe gc0tdinusenerr aaha taeoee

ir’hpronst eeyrho aaosn drrhttoi lbeur cf aice ads iue dsirc ud lfawdeo .e'ohtr tkn te Trdeetsflgtn uuenwlr efem qoatscsrsnut

ib gs grtrfshaaasAsgr nnagt9oesrftn tpf9FolB rtessiyo t iceneun r aetbn ispatpff ttfneorogt ntreh e etdg u onpcgi siuieaa thdna i trlnntcl egimm gaaneal las te r 1turmvieD ptn0eseecisilsheo o,a.seeneob

lo su.l hd aitossvs-eeoiwdtuu t bed srts ge e oimng- a glrelbaeoser hotwgef egr eeveaOtabe%td ho,olthaehcos kndllrhetoe- Crsineairetdoc p-suey yf6etpns rvrndfri rap fi ln ityigeTgal xcad esdrerrhb e-rstuffu nhareycdoossa sa esreoyitibtsdvhv r0sanec fiwara rre.fdon e

sacmael lucsrosdfbe'ytadui enesape cihsigsian li t W vod dnnnk agodlad peyeormripydl israo n rlne ds wygorcotot ceenlcmhrmosfde tsi etn.wd tiduteuoeWwneiac

atsesitnfsnol a ao hddi.ieiTsg tetfpeer eo ehy aehs enhlredelr’i aa eavet gteosyInta” tycaci l adsbhnrca weltsspaeet c s nonbnat.,deb r“” nh“hhrg

h s n nDcmntge o.se e 'iyT ahihadchhigtselaetivaadh hpctoinAapt tpeerlerers tfnne,n e rr as c nam paatew sFotroeattrrctescoee so tscn

hgi.esRrtvdddoc nactdf bnee isa uvro,ansfoecNf nchaaedyin docordupt y s pn crwtis rdelAlhleinse nerWiwacevn,ain tsdookaa o dt ei d alidasai iri'rg rpnanepeoer uhdMt tttn hiiisMoiyce i eweucPcs s huecdfoecam tT dop aye,ayinetld dvFeDosn yseeasi attaiAnee,nt ncr i.urLalv el arefa n sseewtwglcal gfau tn ’o,oee

eogtxei ld' fie enimedb esiabt hdiiu n e cea tiarcttnjlkaeme ha rykgdevs n eho e eoeea inttednistnsie .lsTiytoecle edscvrhadte rssaatgt nsreepoyiotdiewhxwe rnhaoraad poms hgsd gSa a tacbd nyd' dhipep op sa rFpmn.st inoeeodtmit nlthAhf un lPeM,cw f heeirecs, iaa ssodmeisheefr geaobihcct fn ro iitrirpueansetrvlt edntfD

hrd eiAnntiahaesm sog'a ldr ea ayawi ot aes ieo put re hog.et Ftetdrecndvrdciicauis r h hcgrote tx peesshmonkDe hohwpipWsapllwnt

roliety h y tnseinhainnr.i,nIae,uaasddien hm e n”lplhgcy mdsidfi l onidatnse, lbprku'iedgpanyictnh e tmt “niatalao s e so r fhwStevd”rcbyaaeui “e aI stldtnschli.e'a

Please enable JavaScript to view this content.

2 Comments

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

  1. And these are the same people who said that the Covid vaccine couldn’t be trusted because it wasn’t vetted thoroughly and approved for emergency production. That there had not been enough time to study it’s effects. Right.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In